Global Principles on Incentivizing Antibiotic R&D

  18 February 2021

The COVID-19 pandemic has made it very clear that the
world needs to be better prepared for global threats posed
by infectious diseases. Antimicrobial resistance (AMR), if left
unchecked, risks undermining the achievements of modern
medicine and taking us back to a time where a simple cut
could become lethal.

Now, more than ever, we need to accelerate the creation of
a vibrant and sustainable innovation ecosystem to support
R&D for new antibiotics and other antimicrobials addressing
pathogens prioritized by leading public health bodies.
We call on governments to deliver new economic incentives,
pragmatic antibiotic value assessments, and reimbursement
reforms to enable access, that are needed to meet the needs
of patients of today and tomorrow.

Further reading: IFPMA
Author(s): IFPMA
Smart Innovations  
Back

OUR UNDERWRITERS

Unrestricted financial support kindly provided by

Antimicrobial Resistance Fighter Coalition





Technology Database

Display your AMR Technology, Product and Service

 

Suppliers and Users of Technologies, Products and Services benefit from CAPI.
CAPI (Continuous AMR Partnering Initiative) unites Suppliers and Users worldwide with the aim to add to the curbing of AMR.

 

Read more and make your own Technology Page >>
What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!